Radiopharm Theranostics
- Home
- Companies
- Radiopharm Theranostics
- Products
- Radiopharm - Model PSA-mAb - ...
Radiopharm - Model PSA-mAb - Radioactive Drugs
PSA-mAb is the invention of Professor David Ulmert formerly of Memorial Sloan Kettering and now UCLA.
Most popular related searches
- PSA-mAb is a proprietary humanised monoclonal antibody, capable of targeting free human prostate kallikrein (PSA) in prostate cancer cells and internalising payload
- The antibody platform enables a radiotheranostic applicable therapy of prostatic cancer through radioimmunotherapy as well as diagnostics of advanced prostate cancer
- 10 000-fold + higher expression of KLK3 (PSA) in prostate tissue, compared to other tissue
- [225Ac]-PSA mAb results in curative treatment by sustained tumour regression and a significant increase in median survival time
- Data demonstrates a stable humanised antibody, without signs of degradation and aggregation
